Investigational drug · Phase 3
V181
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Healthy.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "V181"
First trial start
2025
Jun 11, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "V181", any sponsor or status.
Conditions studied
As listed on its trial records.
- Healthy
Largest trials
Live from ClinicalTrials.gov: studies naming "V181" as an intervention, largest first.
- A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-1)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07013487 · 12,000 participants (planned) · Start Jun 11, 2025 · Primary completion Sep 6, 2031
Drug: V181; Placebo · For: Healthy
Sites: East Jakarta, Indonesia; Jakarta, Indonesia; North Jakarta, Indonesia · 41 sites in all
- Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002)Pivotal-lookingCompleted
Butantan InstituteGovernment (non-federal)
NCT05710224 · 1,364 participants · Start Feb 15, 2023 · Primary completion Jan 22, 2024
Drug: V181; Butantan - DV · For: Dengue
Sites: Bento Gonçalves, Brazil; Caxias do Sul, Brazil; Ijuí, Brazil · 14 sites in all
- Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05507450 · 1,271 participants · Start Sep 7, 2022 · Primary completion Jun 5, 2023
Drug: V181 High-Potency Level; V181 Mid-Potency Level and 2 more · For: Dengue Disease; Dengue Virus
Sites: San Diego, California; Miami, Florida; Rochester, New York · 32 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Safety and Immunogenicity of the Live-Attenuated Quadrivalent Dengue Vaccine V181 Compared With Butantan-DV Among Healthy Adults in Brazil: A Randomized, Double-Blind, Phase 2 Trial.
Alexanderian D, Ramos F, Chatterjee S, et al. · Clin Infect Dis 2026
- Evolutionarily conserved hydrophobicity and sterics in TM3/TM4 balance Orai1 pore opening.
Fröhlich M, Radi¡kovik T, Hopl V, et al. · Protein Sci 2026
- Resistance Screening and Targeted Metabolomics Identify Potential Biomarkers for Resistance in African Eggplant Against Fusarium elaeidis Wilt.
Okorley BA, Ravnskov S, Brentu FC, et al. · Physiol Plant 2025
- Highlights and hot topics in GPCR research from 'Down Under'.
Smith NJ, May LT, Grimsey NL · Br J Pharmacol 2024
- The small-molecule formyl peptide receptor biased agonist, compound 17b, is a vasodilator and anti-inflammatory in mouse precision-cut lung slices.
Studley WR, Lamanna E, Martin KA, et al. · Br J Pharmacol 2024
- Molecular insights into orphan G protein-coupled receptors relevant to schizophrenia.
Lu Y, Hatzipantelis CJ, Langmead CJ, et al. · Br J Pharmacol 2024
Also in development for Healthy
- DTap-HepB-IPV-Hib vaccineHexyon, Infanrix hexaPhase 34 trials
Sanofi · Healthy Volunteers, Meningococcal Immunization, Pneumococcal Immunization
- Prevenar 20Phase 31 trial
Pfizer · Healthy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.